NASDAQ · SANA
Healthcare · Biotechnology
$3.16
Down-$0.24 (-7.59%)
Updated Sep 16, 2026, 8:21 PM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SANA closed at $3.16 after 20 trading sessions, down 12.95% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $3.20 | $3.20 | $3.075 | $3.16 | 2.47M |
| Sep 14, 2026 | $3.135 | $3.25 | $3.10 | $3.20 | 2.38M |
| Sep 11, 2026 | $3.13 | $3.165 | $3.01 | $3.13 | 3.28M |
| Sep 10, 2026 | $3.10 | $3.19 | $3.00 | $3.09 | 4.62M |
| Sep 9, 2026 | $3.51 | $3.525 | $3.16 | $3.17 | 8.65M |
| Sep 8, 2026 | $3.78 | $3.83 | $3.395 | $3.45 | 4.99M |
| Sep 4, 2026 | $3.86 | $3.915 | $3.81 | $3.85 | 1.24M |
| Sep 3, 2026 | $3.93 | $3.9599 | $3.80 | $3.92 | 2.64M |
| Sep 2, 2026 | $3.82 | $4.08 | $3.795 | $3.89 | 2.14M |
| Sep 1, 2026 | $3.82 | $3.915 | $3.72 | $3.83 | 1.7M |
| Aug 31, 2026 | $3.87 | $3.90 | $3.76 | $3.87 | 2.23M |
| Aug 28, 2026 | $4.05 | $4.115 | $3.89 | $3.93 | 2.14M |
| Aug 27, 2026 | $4.16 | $4.215 | $4.07 | $4.09 | 1.72M |
| Aug 26, 2026 | $4.07 | $4.19 | $4.04 | $4.16 | 2.29M |
| Aug 25, 2026 | $3.88 | $4.15 | $3.85 | $4.10 | 3M |
| Aug 24, 2026 | $3.89 | $3.89 | $3.71 | $3.78 | 1.92M |
| Aug 21, 2026 | $3.78 | $4.0951 | $3.74 | $3.91 | 2.93M |
| Aug 20, 2026 | $4.06 | $4.08 | $3.73 | $3.74 | 2.75M |
| Aug 19, 2026 | $3.71 | $4.12 | $3.67 | $4.10 | 5.91M |
| Aug 18, 2026 | $3.67 | $3.68 | $3.5602 | $3.63 | 2.1M |
The latest Smart Investors Daily articles mentioning SANA.
SANA research
Company profile and research snapshot.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | B of A Securities | Buy | — |
| Apr 14, 2026 | Wedbush | Outperform | — |
| Mar 4, 2026 | HC Wainwright & Co. | Buy | — |
| Jan 6, 2026 | B of A Securities | Buy | — |
| Nov 7, 2025 | Wedbush | Outperform | — |
Generated Sep 16, 2026, 7:18 PM
Sana Biotechnology shares declined 4.95% today despite the company's presentation at the Morgan Stanley 24th Annual Global Healthcare Conference. The sell-off appears to reflect broader market sentiment rather than negative company-specific news, as SANA used the platform to discuss its pipeline and strategic direction.
Bottom line: SANA's 4.95% decline appears driven by a lack of major catalysts from its Morgan Stanley conference presentation rather than fundamental negative news. Long-term investors should monitor upcoming clinical data, regulatory progress, and manufacturing milestones as the key drivers of future valuation, while near-term volatility may persist as the market awaits concrete validation of the company's therapeutic candidates.
SeekingAlpha · Sep 14, 2026
Sana Biotechnology, Inc. (SANA) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 4:50 PM EDTCompany ParticipantsSteven Harr -...
SeekingAlpha · Sep 10, 2026
SeekingAlpha · Sep 10, 2026
Sana Biotechnology, Inc. (SANA) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 9:30 AM EDTCompany ParticipantsSteven Harr - President, CEO...
Yahoo · Sep 1, 2026
SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor conferences in September. The presentations will feature a business overview and update. Sana will present at the 2026 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Tuesday, September 8, 2026.Sana will present at Citi’s 2026 Biopharma Back-to-School Conf
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SANA.
